LY6G6D and neoplasm: In this report, we describe the identification of LY6G6D as a tumor selectively expressed antigen in CRC, and the generation of a LY6G6D/CD3 bi-specific antibody to potently redirect T cells into LY6G6D expressing CRC cells.